Argenx
ARGX
#454
Rank
NZ$93.93 B
Marketcap
NZ$1,501
Share price
3.37%
Change (1 day)
59.13%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total debt

Total debt on the balance sheet as of December 2025 : NZ$80.95 Million

According to Argenx 's latest financial reports the company's total debt is NZ$80.95 Million. A companyโ€™s total debt is the sum of all current and non-current debts.

Argenx - Total debt on balance sheet (from 2017 to 2020)

Total debt by year

Year Total debt Change
2025-12-31NZ$81.42 M17.59%
2024-12-31NZ$69.24 M118.96%
2023-12-31NZ$31.62 M61.59%
2022-12-31NZ$19.57 M16.6%
2021-12-31NZ$16.78 M25.41%
2020-12-31NZ$13.38 M23.16%
2019-12-31NZ$10.86 M
2018-12-31N/A
2017-12-31N/A
2013-12-31N/A-100%
2012-12-31NZ$3.59 M-1.4%
2011-12-31NZ$3.64 M